Sixty-seventh Legislative Assembly of North Dakota

SENATE BILL NO. 2183

Introduced by

Senators Dever, Mathern

Representatives Hanson, Keiser, Pyle, Schauer

1 A BILL for an Act to create and enact section 26.1-36-09.16 of the North Dakota Century Code, 2 relating to accident and health insurance coverage of diabetes drugs and supplies; to amend-3 and reenact section 26.1-36.6-03 of the North Dakota Century Code, relating to public-4 employees self-insurance health plans; to provide for application; to provide an effective date; 5 and to declare an emergency. for an Act to create and enact section 54-52.1-04.20 of the North 6 Dakota Century Code, relating to public employee insulin drug benefits; to amend and reenact 7 subsection 2 of section 26.1-36.6-03 of the North Dakota Century Code, relating to 8 self-insurance health plans; to provide for a report; to provide for application; to provide an 9 expiration date; and to declare an emergency.

10 BE IT ENACTED BY THE LEGISLATIVE ASSEMBLY OF NORTH DAKOTA:

11	SECTION 1. Section 26.1-36-09.16 of the North Dakota Century Code is created and
12	enacted as follows:
13	26.1-36-09.16. Insulin drug and supply cost-sharing limitations and formulary
14	<u>limitations.</u>
15	— 1. As used in this section:
16	a. "Insulin drug" means a prescription drug that contains insulin and is used to treat
17	a form of diabetes mellitus. The term does not include an insulin pump, an
18	electronic insulin-administering smart pen, or a continuous glucose monitor, or
19	supplies needed specifically for the use of such electronic devices. The term
20	includes insulin in the following categories:
21	(1) Rapid-acting insulin;
22	——————————————————————————————————————
23	(3) Intermediate-acting insulin;
24	(4) Long-acting insulin;

Sixty-seventh Legislative Assembly

1		(5) Premixed insulin product;	
2		(6) Premixed insulin/GLP-1 RA product; and	
3	-	(7) <u>Concentrated human regular insulin.</u>	
4		b. "Medical supplies for insulin dosing and administration" means supplies nee	eded
5		for proper insulin dosing, as well as supplies needed to detect or address m	edical_
6		emergencies in an individual using insulin to manage diabetes mellitus. The	term_
7		does not include an insulin pump, an electronic insulin-administering smart	p en,
8		or a continuous glucose monitor, or supplies needed specifically for the use	of
9		such electronic devices. The term includes:	
10		(1) Blood glucose meters;	
11		(2) Blood glucose test strips;	
12		(3) Lancing devices and lancets;	
13		(4) Ketone testing supplies, such as urine strips, blood ketone meters, and	<u>+</u>
14		blood ketone strips;	
15		(5) Glucagon, injectable or nasal forms;	
16		(6) Insulin pen needles; and	
17		(7) Insulin syringes.	
18		c. "Pharmacy or distributor" means a pharmacy or medical supply company, or	<u>r-</u>
19		other medication or medical supply distributor filling a covered individual's	
20		prescriptions.	
21		d. "Policy" means an accident and health insurance policy, contract, or evidence	ce of
22		coverage on a group, individual, blanket, franchise, or association basis.	
23	<u> 2.</u>	An insurer may not deliver, issue, execute, or renew a policy that provides covera	ige
24		for an insulin drug or medical supplies for insulin dosing and administration unles	s the
25		policy complies with this section.	
26	<u> 3.</u>	The policy must provide cost-sharing for a thirty-day supply of:	
27		a. Prescribed insulin drugs which may not exceed twenty-five dollars per pharm	nacy
28		or distributor, regardless of the quantity or type of insulin drug used to fill the	}
29		covered individual's prescription needs.	
30		b. Prescribed medical supplies for insulin dosing and administration, the total of	<u>)f</u>
31		which may not exceed twenty-five dollars per pharmacy or distributor, regard	dless

30

31

26.1-36-08, 26.1-36-08.1, 26.1-36-09, 26.1-36-09.1, 26.1-36-09.2, 26.1-36-09.3,

1	26.1-36-09.11, 26.1-36-09.12, 26.1-36-09.13, 26.1-36-09.14, 26.1-36-09.15,
2	26.1-36-09.16, 26.1-36-11, 26.1-36-12.2, 26.1-36-20, 26.1-36-21, 26.1-36-22,
3	26.1-36-23.1, and 26.1-36-43.
4	SECTION 3. APPLICATION. This Act applies to a policy delivered, issued, executed, or
5	renewed after June 30, 2021.
6	SECTION 4. EFFECTIVE DATE. This Act becomes effective July 1, 2021.
7	SECTION 5. EMERGENCY. This Act is declared to be an emergency measure.
8	SECTION 1. AMENDMENT. Subsection 2 of section 26.1-36.6-03 of the North Dakota
9	Century Code is amended and reenacted as follows:
10	2. The following health benefit provisions applicable to a group accident and health
11	insurance policy under chapter 26.1-36 apply to a self-insurance health plan and are
12	subject to the jurisdiction of the commissioner: 26.1-36-06, 26.1-36-06.1, 26.1-36-07,
13	26.1-36-08, 26.1-36-08.1, 26.1-36-09, 26.1-36-09.1, 26.1-36-09.2, 26.1-36-09.3,
14	26.1-36-09.5, 26.1-36-09.6, 26.1-36-09.7, 26.1-36-09.8, 26.1-36-09.9, 26.1-36-09.10,
15	26.1-36-09.11, 26.1-36-09.12, 26.1-36-09.13, 26.1-36-09.14, 26.1-36-09.15,
16	26.1-36-11, 26.1-36-12.2, 26.1-36-20, 26.1-36-21, 26.1-36-22, 26.1-36-23.1, and
17	26.1-36-43. Section 54-52.1-04.20 applies to a self-insurance health plan and is
18	subject to the jurisdiction of the commissioner.
19	SECTION 2. Section 54-52.1-04.20 of the North Dakota Century Code is created and
20	enacted as follows:
21	54-52.1-04.20. Health insurance benefits coverage - Insulin drug benefits.
22	1. As used in this section:
23	a. "Cost-sharing" includes copayments and coinsurance.
24	b. "Insulin drug" means a prescription drug that contains insulin and is used to treat
25	a form of diabetes mellitus. The term does not include an insulin pump, an
26	electronic insulin-administering smart pen, or a continuous glucose monitor, or
27	supplies needed specifically for the use of such electronic devices. The term
28	includes insulin in the following categories:
29	(1) Rapid-acting insulin;
30	(2) Short-acting insulin;
31	(3) Intermediate-acting insulin;

1		(4) Long-acting insulin;
2		(5) Premixed insulin product;
3		(6) Premixed insulin/GLP-1 RA product; and
4		(7) Concentrated human regular insulin.
5		c. "Pharmacy or distributor" means a pharmacy or medical supply company, or
6		other medication or medical supply distributor filling a covered individual's
7		prescriptions.
8	2.	The board shall provide health insurance benefits coverage that provides cost-sharing
9		for a thirty-day supply of prescribed insulin drugs which does not exceed twenty-five
10		dollars per pharmacy or distributor, regardless of the quantity or type of insulin drug
11		used to fill the covered individual's prescription needs.
12	3.	The coverage may not allow a pharmacy benefits manager or the pharmacy or
13		distributor to charge, require the pharmacy or distributor to collect, or require a
14		covered individual to make, a cost-sharing payment for a covered insulin drug in an
15		amount that exceeds the amount of the cost-sharing payment for the prescribed
16		insulin drugs under subsection 2.
17	4.	Subsection 2 does not require the coverage to include cost-sharing and does not
18		prevent the implementation of cost-sharing in an amount less than the amount
19		specified under subsection 2. Subsection 2 does not limit cost-sharing on an insulin
20		pump, an electronic insulin-administering smart pen, or a continuous glucose monitor.
21		This section does not limit whether coverage classifies an insulin pump, an electronic
22		insulin-administering smart pen, or a continuous glucose monitor as a drug or as a
23		medical device or supply.
24	SEC	CTION 3. APPLICATION. This Act applies to health benefits coverage that begins after
25	June 30	, 2021, and which does not extend past June 30, 2023.
26	SEC	CTION 4. PUBLIC EMPLOYEES RETIREMENT SYSTEM - INSULIN DRUG
27	BENEF	ITS. Pursuant to section 54-03-28, the public employees retirement system shall
28	prepare	and submit for introduction a bill to the sixty-eighth legislative assembly to repeal the
29	expiration	on date for this Act and to extend the coverage of insulin drug benefits to all group and
30	individua	al health insurance policies. The public employees retirement system shall append a
31	report to	the bill regarding the effect of the insulin drug benefits requirement on the system's

- 1 health insurance programs, information on the utilization and costs relating to the coverage, and
- 2 a recommendation regarding whether the coverage should be continued.
- 3 **SECTION 5. EXPIRATION DATE.** This Act is effective through July 31, 2023, and after that
- 4 date is ineffective.
- 5 **SECTION 6. EMERGENCY.** This Act is declared to be an emergency measure.